Home

AMARIN CORPORATION

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. These trials are investigating the efficacy of ARM101 in lowering triglycerides in patients with very high triglycerides (>500mg/dl) and in patients with mixed dyslipidemia who are taking statins. Amarin’s cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease.

AMR101 for Hypertriglyceridemia

AMR101 is prescription grade, ultra-pure (>96%) ethyl ester of eicosapentaenoic acid (ethyl-EPA; an omega-3 fatty acid). AMR101 is being positioned as a best-in-class prescription medicine for treating patients with high or very high triglycerides.

There is significant scientific and clinical evidence supporting the efficacy of ethyl-EPA in lowering triglyceride levels. AMR101 has been studied in over 1,000 patients in double-blind, placebo-controlled studies, including over 100 patients studied for greater than 12-months.

It is estimated that more than 27 million people in the US have elevated triglyceride levels, which are associated with the increased risk of developing coronary artery disease as well as being a component of certain other metabolic disorders, such as diabetes and obesity.

read more
Download